6780. Piperazine hog and poultry wormer. (F.D.O. No. 45790. S. No. 22-037 R.) QUANTITY: 31 1-qt. btls. at Middlebury, Ind. SHIPPED : 9-7-60, from Toledo, Ohio, by Miller Chemical Co. LABEL IN PART : "Piperazine Hog & Poultry Wormer Active Ingredient: Each 100 cc Contains 17.08 grams of Piperazine Base Hexahydrate. * * * Directions for use-Miller's Piperazine-A Liquid Wormer For Swine & Poultry." LIBELED : 5-5-61, N. Dist. Ind. CHARGE: 502(a)-when shipped, the label contained false and misleading rep- resentations that the article was adequate and effective when used as directed in treatment for removing or controlling nodular and round worms from swine and round worms (Ascwridia galli) from poultry. DISPOSITION : 6-16-61. Default-destruction. INDEX TO NOTICES OF JUDGMENT D. D. N. J. NOS. 6741 TO 6780 PRODUCTS N.J. No. Abunda Beauty device 6776 Air purifier device 6775 All-In-One capsules 6764 Altocaps capsules 6745 Androgenic substance 6745 Armatinic liquid 6742 Arthritis, remedy for. See Rheu- matism, remedy for. Asthma, remedy for (device) 6775 Barium sulfate 6752 Bhaji tablets 6761 Biphetamine-T 20 6743 12% 6743 Bursitis, remedy for. See Rheu- matism, remedy for. Bust developer (device) 6776 Cernelle PoUitabs 6771 Chick starter (medicated) 6760 Ohirata, powdered 6761 Coach-Aid Special Formula pills. 6773 Stim-O-Stam Food Supplement tablets 6773 Cosmetics (subject to the drug provisions of the Act) __ 6777,6778 Cough syrup, Olbas 6768 Delamer minerals in sea water 6766 Deronil tablets 6747 N.J. No. Devices 6748, 6749, 6758, 6775-6778 Duodenal ulcers, remedy for 6762 Electronic Magnetic Model G de- vice 6748, 6749 Equanil tablets (imitation) 6757 Erasurage device 6777 Family Plan Vitafood Supple- ment tablets 6774 Ferbetex tablets 6741 Ferrous sulfate tablets 6751 Figuremaker device 6778 Hay fever, remedy for (device). 6775 Insta-Pep tablets * 6746 Iro-Jex injectable 6744 Isoproterenol hydrochloride sub- lingual tablets 6754 Kongo-Kit massage device 6779 L.G.B. 12-100 6755 Lecitabs 6763 Lecithin tablets 6763 Lumbago, remedy for. See Rheu- matism, remedy for. Mavene wafers 6762 Micronaire device 6775 Neuralgia, remedy for. See Rheumatism, remedy for. ?See also No. 6760. 1 (6746) Prosecution contested. Contains memorandum and order of the court. The cases reported herewith were instituted in the United States district courts by United States attorneys, acting upon reports submitted by the Depart- ment of Health, Education, and Welfare. They involve drugs and devices which were adulterated or misbranded within the meaning of the Act when intro- duced into and while in interstate commerce or while held for sale after shipment in interstate commerce. These cases involve seizure proceedings in which de- crees of condemnation were entered after default or consent. The seizure proceedings are civil actions taken against the goods alleged to be in violation. Published by direction of the Secretary of Health, Education, and Welfare. GEO. P. LABEICK, Commissioner of Food and Drugs. WASHINGTON, D.C, November 29, 1962. CONTENTS* Page New drugs shipped without effec- tive application 190 Drugs in violation of prescription labeling requirements 192 Drugs and device actionable because of failure to bear adequate directions or warning statements 197 Drugs for human use 197 Drugs for veterinary use 198 Page Drugs and devices actionable because of deviation from official or own standards 199 Drugs for human use 199 Drug for veterinary use 201 Drugs and devices actionable because of false and misleading claims 201 Drug actionable because of omis- sion of, or unsatisfactory in- gredient statements 212 Index 213 *For failure to bear a label containing an accurate statement of the quantity of the contents. See Nos. 6786,6794,6820; failure to bear a label containing the name and place of business of the manufacturer, packer, or distributor, Nos. 6783, 6784, 6786, 6801 6815, 6820; cosmetics, actionable under the drug provisions of the SECTIONS OF FEDERAL FOOD. DRUG. AND COSMETIC ACT INVOLVED IN VIOLATIONS REPORTED IN D.D.N J. NOS. 6781-6820 Adulteration, Section 501(c), the article was not subject to the provisions of Section 501(b), and its strength differed from, or its purity or quality fell below, that which it purported or was represented to possess. Misbranding, Section 502(a), the labeling of the article was false and mislead- ing ; Section 502(b), the article was in package form, and it failed to bear a label containing (1) the name and place of business of the manufacturer, packer, or distributor, and (2) an accurate statement of the quantity of the contents in terms of weight, measure, or numerical count; Section 502(e), the article was a drug not designated solely by a name recognized in an official compendium, and its label failed to bear (1) the common or usual name of the drug, and (2), in the case where the article was fabricated from two or more ingredients, the com- mon or usual name of each active ingredient; Section 502(f), the labeling of the article failed to bear (1) adequate directions for use, and (2) adequate warn- ings against use in those pathological conditions, or by children, where its use may be dangerous to health, or against unsafe dosage or methods or duration of administration or application, in such manner and form, as are necessary for the protection of users; Section 503(b)(4), the article was a drug subject to Section 503(b) (1), and its label failed to bear the statement "Caution: Federal law prohibits dispensing without prescription." New-drug violation, Section 505(a), the article was a new drug within the meaning of Section 201 (p), which was introduced into interstate commerce, and an application filed pursuant to Section 505(b) was not effective with respect to such drug. NEW DRUGS SHIPPED WITHOUT EFFECTIVE APPLICATION